NextCure (NXTC) Retained Earnings (2018 - 2026)
NextCure (NXTC) posted quarterly Retained Earnings of $472.5 million for Q1 2026, up 220.81% year-over-year from $147.3 million in Q1 2025, and up 208.37% quarter-over-quarter from -$436.0 million in Q4 2025.
NextCure (NXTC) Retained Earnings (2018 - 2026) Analysis & Trends
NextCure's Retained Earnings history runs 9 years deep, the most recent figure standing at $472.5 million for Q1 2026.
- In Q1 2026, Retained Earnings rose 220.81% year-over-year to $472.5 million; the TTM figure through Mar 2026 stood at $472.5 million (up 220.81% YoY), while the FY2025 annual figure was -$436.0 million, down 197.84% from the prior year.
- Retained Earnings for Q1 2026 stood at $472.5 million, up from -$436.0 million in the prior quarter.
- The five-year high for Retained Earnings was $472.5 million in Q1 2026, with the low at -$436.0 million in Q4 2025.
- The 5-year median for Retained Earnings is -$225.5 million (2022), against an average of -$93.9 million.
- The sharpest annual moves came in 2022 and 2024: Retained Earnings sank 115565.64% in 2022, then soared 200821.62% in 2024.
- NextCure's Retained Earnings stood at -$1.5 million in 2022, then jumped by 85.14% to -$222000.0 in 2023, then jumped by 200821.62% to $445.6 million in 2024, then slumped by 197.84% to -$436.0 million in 2025, then jumped by 208.37% to $472.5 million in 2026.
- Business Quant data shows NXTC's Retained Earnings at $472.5 million in Q1 2026, -$436.0 million in Q4 2025, and -$426.5 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 15.69 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 37.62 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 558.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 5.10 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 13.05 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -6.33 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 20.91 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 6.57 Bn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 4.38 Bn |
| 10 | NextCure | 33.72 Mn | 33.72 Mn | - | 472.82 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 472.82 Mn |
| Mar 31, 2026 | 472.49 Mn |
| Dec 31, 2025 | -435.98 Mn |
| Sep 30, 2025 | -426.50 Mn |
| Jun 30, 2025 | -417.90 Mn |
| Mar 31, 2025 | -391.11 Mn |
| Dec 31, 2024 | 445.60 Mn |
| Sep 30, 2024 | -368.53 Mn |
| Jun 30, 2024 | -356.99 Mn |
| Mar 31, 2024 | 440.79 Mn |
| Dec 31, 2023 | -222,000.00 |
| Sep 30, 2023 | -310.02 Mn |
| Jun 30, 2023 | -925,000.00 |
| Mar 31, 2023 | 432.83 Mn |
| Dec 31, 2022 | -1.49 Mn |
| Sep 30, 2022 | -244.46 Mn |
| Jun 30, 2022 | -225.55 Mn |
| Mar 31, 2022 | -207.63 Mn |
| Dec 31, 2021 | 421.05 Mn |
| Sep 30, 2021 | -170.09 Mn |